MX2009012598A - Formas de dosis que comprenden vx-950 y su regimen de dosificacion. - Google Patents

Formas de dosis que comprenden vx-950 y su regimen de dosificacion.

Info

Publication number
MX2009012598A
MX2009012598A MX2009012598A MX2009012598A MX2009012598A MX 2009012598 A MX2009012598 A MX 2009012598A MX 2009012598 A MX2009012598 A MX 2009012598A MX 2009012598 A MX2009012598 A MX 2009012598A MX 2009012598 A MX2009012598 A MX 2009012598A
Authority
MX
Mexico
Prior art keywords
relates
dosage regimen
dose forms
compositions
kits
Prior art date
Application number
MX2009012598A
Other languages
English (en)
Inventor
Lindsay Mcnair
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2009012598A publication Critical patent/MX2009012598A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a las terapias antivirales y a las composiciones para tratar o prevenir infecciones por hepatitis C en pacientes, y se refiere a otros métodos descritos en la presente. La invención también se refiere a los kits y paquetes farmacéuticos que comprenden composiciones y formas de dosis. La invención también se refiere a los procesos para preparar estas composiciones, dosis, kits, y paquetes.
MX2009012598A 2007-05-21 2008-05-21 Formas de dosis que comprenden vx-950 y su regimen de dosificacion. MX2009012598A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93110807P 2007-05-21 2007-05-21
US99443007P 2007-09-19 2007-09-19
PCT/US2008/006572 WO2008144072A1 (en) 2007-05-21 2008-05-21 Dose forms comprising vx- 950 and their dosage regimen

Publications (1)

Publication Number Publication Date
MX2009012598A true MX2009012598A (es) 2009-12-07

Family

ID=39597267

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012598A MX2009012598A (es) 2007-05-21 2008-05-21 Formas de dosis que comprenden vx-950 y su regimen de dosificacion.

Country Status (8)

Country Link
US (1) US20100189688A1 (es)
EP (1) EP2157974A1 (es)
JP (2) JP2010528013A (es)
CN (1) CN101854936A (es)
AU (1) AU2008254435A1 (es)
CA (1) CA2688554A1 (es)
MX (1) MX2009012598A (es)
WO (1) WO2008144072A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
KR20110074870A (ko) 2008-09-24 2011-07-04 버텍스 파마슈티칼스 인코포레이티드 간염을 치료하기 위한 ｐｅｇ-인터페론, 리바비린 및 ｖｘ-950을 포함하는 치료 요법
WO2010053942A1 (en) * 2008-11-05 2010-05-14 Vertex Pharmaceuticals Incorporated Methods for treating hepatitis c virus infection
JP2012517478A (ja) * 2009-02-12 2012-08-02 バーテックス ファーマシューティカルズ インコーポレイテッド ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CA2788348A1 (en) 2010-01-29 2011-08-04 Vertex Pharmaceuticals Incorporated Therapies for treating hepatitis c virus infection
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
AR082215A1 (es) 2010-07-14 2012-11-21 Vertex Pharma Composicion farmaceutica agradable al paladar
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
WO2013116339A1 (en) 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms

Also Published As

Publication number Publication date
CN101854936A (zh) 2010-10-06
JP2014132015A (ja) 2014-07-17
CA2688554A1 (en) 2008-11-27
WO2008144072A1 (en) 2008-11-27
US20100189688A1 (en) 2010-07-29
AU2008254435A1 (en) 2008-11-27
JP2010528013A (ja) 2010-08-19
EP2157974A1 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
MX2007005179A (es) Formas de dosificacion.
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
MD20150062A2 (ro) Compuşi antivirali
MX348481B (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MX359989B (es) Fármacos antivirales para el tratamiento de la infección por arenavirus.
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
MY169159A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2012011222A (es) Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
MX2010002278A (es) Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
HK1123733A1 (en) Viral hepatitis treatment
WO2007135172A3 (en) Cladribine regimen for treating multiple sclerosis
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
MX2009013501A (es) Compuestos piperidinicos y sus usos.
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
EA201071230A1 (ru) Лечение инфекций вирусом гепатита с телапревиром (vx-950) у пациентов, не отвечающих на лечение пегилированным интерфероном-альфа-2а/2в и рибавирином
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
MY166063A (en) Intravenous antiviral treatments
UA103907C2 (ru) Терапевтический режим лечения гепатита, который включает пег-интерферон, рибавирин и vx-950
TNSN06305A1 (en) Treatment regimen for camptothecin derivatives
TN2013000134A1 (en) Combination therapy for treating hcv infection

Legal Events

Date Code Title Description
FA Abandonment or withdrawal